NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UnitedHealth Group Incorporated (NYSE: UNH) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UnitedHealth you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/unitedhealth-group-incorporated. Investors have until July 7, 2025, to ask the ...

Investor Presentation May 2025 Legal LGTM (PJR) 5.13.25 via Slack Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income from continuing operations, Adjusted SG&A, Adjusted SG&A as a percentage of revenue, Insurance BER (non-GAAP measures, as defined herein) ...

I am rating Oscar Health, Inc. (NYSE: OSCR ) as a hold due to a proposed steep budget cut of $163 billion in the 2026 budget estimates. The Health and Human Services (HHS) cut is estimated to be $33.3 billion, an $18 billion cutFirst Principles Partners is an equity research analyst specializing in technology, innovation, and sustainability investment. My unique approach, "First Principles," involves breaking down complex problems to their most basic elements in terms of financial and technology, enabling m ...

Core Viewpoint - UnitedHealth Group's stock price plummeted by $65.71 (-17%) following the resignation of CEO Andrew Witty and the withdrawal of its 2025 guidance, which was issued less than a month prior [1] Group 1: Company Developments - The resignation of CEO Andrew Witty and the withdrawal of the 2025 guidance led to a significant drop in UnitedHealth's share price [1] - A securities class action lawsuit has been filed against UnitedHealth after approximately $170 billion of its market capitalization was lost on April 17, 2025 [2] - The lawsuit claims that UnitedHealth made false and misleading statements regarding its financial guidance for FY 2025, which was initially set at a net EPS of $28.15 to $28.65 and adjusted EPS of $29.50 to $30.00 [3][4] Group 2: Financial Impact - Following the announcement on April 17, 2025, UnitedHealth's share price fell by 22%, reflecting investor reaction to the slashed guidance [5] - The revised guidance on April 17 indicated a net EPS of $24.65 to $25.15 and adjusted EPS of $26.00 to $26.50, significantly lower than previous estimates [4] Group 3: Corporate Strategy and Public Perception - UnitedHealth has faced scrutiny for its corporate strategy of denying health coverage to boost profits, which has led to public outrage and regulatory scrutiny [6] - The murder of Brian Thompson, the CEO of UnitedHealthcare, on December 4, 2024, intensified negative sentiment towards UnitedHealth, with many Americans expressing animosity towards the company [6] - Despite the changing corporate strategies in response to public pressure, UnitedHealth continued to issue unrealistic financial guidance [6]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding Medicaid cost trends and premium negotiations [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance Health common stock between April 18, 2024, and October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately reflected in its guidance, while in reality, the acuity and utilization of Medicaid members were increasing significantly [5]. - The lawsuit suggests that the members being removed from Medicaid were healthier than those who remained, which was not accounted for in Elevance's rate negotiations or financial forecasts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - CVS Health shares have increased nearly 38% this month due to stronger-than-expected Q1 2025 results, despite concerns over store closures related to new PBM reform legislation [1][2] Financial Performance - CVS Health reported Q1 2025 adjusted EPS of $2.25 and adjusted operating income of $4.6 billion, exceeding market expectations [5] - The company raised its full-year adjusted EPS guidance to a range of $6 to $6.20, up from $5.75 to $6, reflecting confidence in operational strength across its core businesses [5] Management Changes - Brian Newman was appointed as CFO and Amy Compton-Phillips as CMO, positioning CVS to advance its long-term vision of becoming a trusted healthcare company [6] Digital Innovation - The CVS Health app is enhancing customer engagement by providing better visibility into care and real-time AI recommendations [7] Operational Efficiency - CVS Health is streamlining prior authorizations, with 95% of Aetna's requests processed within 24 hours, and is expanding its bundled cancer care model [8] - The pharmacy segment processes over 1.7 billion prescriptions annually, with strategic investments in technology driving performance [9] Affordability Initiatives - CVS is expanding access to therapies, partnering with Novo Nordisk to offer Wegovy at lower costs and leading the U.S. market with its low-cost Humira biosimilar, generating over $1 billion in savings for clients [10] Strategic Focus - CVS Health will exit the ACA individual exchange markets by 2026 due to losses, focusing instead on Medicare, commercial, and Medicaid plans [11] Regulatory Challenges - CVS is closing 23 pharmacies in Arkansas due to new legislation banning PBMs from owning pharmacies, which CVS argues will limit access and increase drug spending [12][14] Valuation Insights - CVS Health's forward P/E ratio is 9.46X, lower than the S&P 500's 21.37X, but higher than competitors Walgreens Boots and Herbalife [15][17] - The stock's premium may be justified by its scale and strategic focus on digital health and value-based care [17] Analyst Outlook - CVS Health is trading nearly 22% below its average price target according to 22 analysts, indicating strong upside potential [19] Investment Recommendation - Despite regulatory challenges, CVS Health remains a strong long-term investment due to its diversified business model and advancements in digital health [20]

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for alleged violations of federal securities laws during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Elevance misrepresented its monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - It is alleged that while Elevance acknowledged rising Medicaid expenses, the company misled investors by stating that these costs were adequately reflected in its financial guidance for 2024 [3]. - The complaint highlights that the redetermination process led to a significant increase in the acuity and utilization of Medicaid members, contradicting Elevance's representations regarding its financial outlook [3]. Group 2: Investor Participation - Investors who purchased Elevance securities during the Class Period are encouraged to join the lawsuit, with a deadline of July 11, 2025, to request lead plaintiff status [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Group 1: Palantir (PLTR) - Palantir experienced significant growth with sales increasing by 39% year-over-year, raising its current year sales outlook to an estimated $3.9 billion, suggesting a 41% growth year-over-year [2][4] - The customer count grew nearly 40% year-over-year and 8% sequentially, with the highest U.S. commercial total contract value of $810 million, reflecting a 180% year-over-year increase [4] - Analysts have revised their EPS expectations upward, indicating a positive outlook for near-term share performance [4] Group 2: Centene (CNC) - Centene reported adjusted EPS of $2.90 and sales of $46.6 billion, exceeding consensus estimates with earnings up 28% year-over-year [6] - The company raised its 2025 premium and service revenues guidance by $6.0 billion, reflecting a 17% year-over-year improvement [6] - Following the guidance upgrade, analysts expect Centene to post $178.7 billion in revenues for the current fiscal year [9] Group 3: Cboe Global Markets (CBOE) - Cboe posted record adjusted EPS of $2.37, up 21% year-over-year, and record net revenue of $562.5 million, up 13% year-over-year [11] - The company reported record Options net revenue of $352.4 million, reflecting a 15% year-over-year increase, and global FX net revenue of $21.3 million, up 16% year-over-year [12] - Analysts have revised their earnings expectations higher, indicating a favorable near-term earnings outlook [14]

The Dow Jones closed lower by around 270 points to 42,140.43 on Tuesday. The S&P 500 surged 0.72% to 5,886.55, while the Nasdaq Composite jumped 1.61% at 19,010.08 during Tuesday's session. Investors are awaiting earnings results from Sony Group Corporation SONY, Cisco Systems, Inc. CSCO and MakeMyTrip Limited MMYT today. The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks settled mixed on Tuesday ...

Market Overview - Markets traded mostly higher, with the S&P 500, Nasdaq, and Russell 2000 gaining for the third time in four sessions, while the Dow closed down due to a significant drop in UnitedHealthcare's stock [1] - The Dow fell by 269 points, or 0.64%, while the S&P 500, Nasdaq, and Russell 2000 increased by 0.72%, 1.61%, and 0.49%, respectively [1] UnitedHealthcare Performance - UnitedHealthcare's stock has decreased by 47% in the past month following a Q1 earnings report that showed slightly lower earnings and sales, along with lowered guidance for the full year [2] - CEO Andrew Witty has stepped down immediately, and the lowered guidance for 2025 has been completely removed [2] - Chairman Stephen Hemsley, who previously turned around the company, will return in an interim role [3] - UnitedHealthcare currently holds a Zacks Rank 4 (Sell), compared to Zacks Rank 2 (Buy) for competitors Cigna and Centene [3] NVIDIA and AI Sector - The Nasdaq's increase was largely driven by a 5.6% rise in NVIDIA shares, which have surged 38% since early April [4] - NVIDIA is recognized as a leading AI-infrastructure stock, benefiting from increased investments in AI projects [4] Upcoming Earnings and Economic Indicators - Cisco Systems is expected to report fiscal Q3 numbers, projecting a 3.4% earnings growth year over year and a 10.7% increase in sales [5] - The upcoming Producer Price Index (PPI) for April, along with Retail Sales and Weekly Jobless Claims, will be released soon [5]